Advertisement
- United States
- /
- Healthcare Services
- /
- NYSE:CVS
CVS Health Full Year 2024 Earnings: EPS Beats Expectations
CVS Health (NYSE:CVS) Full Year 2024 Results
Key Financial Results
- Revenue: US$372.8b (up 4.5% from FY 2023).
- Net income: US$4.61b (down 45% from FY 2023).
- Profit margin: 1.2% (down from 2.3% in FY 2023). The decrease in margin was driven by higher expenses.
- EPS: US$3.67 (down from US$6.49 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
CVS Health EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 20%.
Looking ahead, revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Healthcare industry in the US.
Performance of the American Healthcare industry.
The company's shares are up 14% from a week ago.
Risk Analysis
Be aware that CVS Health is showing 2 warning signs in our investment analysis and 1 of those is potentially serious...
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:CVS
CVS Health
Provides health solutions in the United States.
Very undervalued average dividend payer.
Similar Companies
Market Insights
Advertisement
Weekly Picks
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.887.9% undervalued
15 followersusers have followed this narrative
1 commentusers have commented on this narrative
11 likesusers have liked this narrative
TO
Tokyo on LVMH Moët Hennessy - Louis Vuitton Société Européenne ·
EU#4 - Turning Heritage into the World’s Strongest Luxury Empire
Fair Value:€750.0429.5% undervalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
6 likesusers have liked this narrative
WE
WealthAP on Alphabet ·
The "Easy Money" Is Gone: Why Alphabet Is Now a "Show Me" Story
Fair Value:US$386.4312.1% undervalued
55 followersusers have followed this narrative
1 commentusers have commented on this narrative
15 likesusers have liked this narrative
Recently Updated Narratives
RE
RecMag on Proximus ·
Proximus: The State-Backed Backup Plan with 7% Gross Yield and 15% Currency Upside.
Fair Value:€17.1354.8% undervalued
37 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
CO
composite32 on SEGRO ·
SEGRO's Revenue to Rise 14.7% Amidst Optimistic Growth Plans
Fair Value:UK£9.3918.8% undervalued
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AL
alex30free on Beijer Ref ·
The Green Consolidator
Fair Value:SEK 128.821.0% overvalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
WE
WealthAP on PayPal Holdings ·
The "Sleeping Giant" Stumbles, Then Wakes Up
Fair Value:US$8249.1% undervalued
85 followersusers have followed this narrative
6 commentsusers have commented on this narrative
35 likesusers have liked this narrative
OO
OOO97 on Neo Performance Materials ·
Undervalued Key Player in Magnets/Rare Earth
Fair Value:CA$25.3320.9% undervalued
75 followersusers have followed this narrative
0 commentsusers have commented on this narrative
19 likesusers have liked this narrative
AN
AnalystConsensusTarget on NVIDIA ·
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$253.0228.7% undervalued
1050 followersusers have followed this narrative
6 commentsusers have commented on this narrative
31 likesusers have liked this narrative
Trending Discussion
HE
Hemingway on Aeva Technologies ·
NVDA+AEVA Agreement is a game changer for the AEVA stock even though it is just a partnership and does not have a roll out until 2028 (which means receivables as early as 2027, I would imagine) This agreement effectively moves the goal posts of profitability for AEVA much closer since this is in addition to the recent Forterra agreement, as well as the (previously announced) European carmaker agreement (which is believed to be Mercedes-Benz and estimated to be worth at least 1 billion in sales alone) Underneath all of this, AEVA has a pre-existing agreement with Daimler Truck. So business seems to be booming, especially with really big name brands…which tends to bring in even more brand names (and thus more agreements/contracts/announcements, etc). This dynamic often creates more coverage from analysts (often with upside stock initial coverage) that I believe will be occurring over the next 3 to 6 months (as professional traders/analysts often research for 2 to 3 months before initiating coverage of a new issue). I also feel that the above momentum increases the likelihood that companies that do not currently utilize 4G LIDAR technology might consider buying AEVA outright. Realistically, even with a substantial premium to the current stock price, the cost of AEVA would be a rounding error for the likes of a company such as Tesla, and certainly would allow them to maintain their technological edge as the competition for self-driving vehicles continues to heat up. However, I think it is equally possible for NVidea to decide to lock-in the AEVA technology for their upcoming autonomous hardware/software package by buying them outright. Obviously, the above factors and recent activity in the AEVA stock are cause for optimism. Of course, this all just one opinion , so please do your own due diligence. Disclaimer: I/We DO trade in this stock from time to time and I/we may (or may not have) a position currently, so again, please do your own due diligence.
0
|0
